NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial

NeuroSense's PrimeC Reduces Key ALS Biomarker in Phase IIb Trial

NeuroSense Therapeutics' combination ALS therapy, PrimeC, demonstrated a statistically significant reduction in TDP-43 protein levels, a key biomarker for ALS progression, in its Phase IIb PARADIGM study. This achievement met the trial's primary endpoint and led to FDA clearance for the global Phase III PARAGON study. Earlier results from PARADIGM showed PrimeC slowed ALS decline by 32.8% at 18 months and offered a 15-month median survival benefit over placebo. PrimeC combines ciprofloxacin and celecoxib, targeting brain inflammation, abnormal microRNA activity, and iron buildup.

• PrimeC achieved a statistically significant reduction in TDP-43 protein levels, a critical biomarker linked to 97% of ALS cases and disease progression, meeting the primary endpoint of the Phase IIb PARADIGM study. This reduction was sustained and durable over an 18-month treatment period, suggesting long-lasting benefits for patients.
• Beyond biomarker reduction, PrimeC previously demonstrated a 32.8% slowing of ALS decline at 18 months and a 15-month median survival benefit over placebo in the PARADIGM study. These positive clinical outcomes have led to FDA clearance for the initiation of the global Phase III PARAGON study, marking a significant step towards market entry.
• PrimeC is a combination therapy of ciprofloxacin and celecoxib, designed to address three key underlying disease mechanisms in ALS: brain inflammation, abnormal microRNA activity linked to gene control, and the buildup of iron in neurons. This dual-pronged approach aims to provide a comprehensive disease-modifying effect.

PrimeC's Multi-Pronged Combination Approach for ALS

Recent clinical investigation in ALS has increasingly moved toward combination and add-on therapy strategies, reflecting the multifactorial nature of motor neuron degeneration. A notable example is the ROCK-ALS trial, a multicenter, randomized, double-blind, placebo-controlled phase 2 study evaluating fasudil — a Rho kinase (ROCK) inhibitor — as an add-on to riluzole in ALS patients. At day 90, fasudil significantly reduced the number of newly affected muscles compared to placebo in a dose-dependent manner, as measured by the Motor Unit Number Index (MUNIX), a quantitative electrophysiological biomarker of lower motor neuron integrity assessed across 10 muscles at baseline, day 26, day 90, and day 180. Baseline MUNIX sum scores also correlated with subsequent ALSFRS-R decline, suggesting prognostic utility. These findings indicate that fasudil may attenuate the spread of lower motor neuron involvement in ALS when layered onto standard-of-care riluzole therapy (NCT03792490).

On the regulatory and pharmacological front, the approved treatment landscape for ALS has expanded considerably. The FDA currently recognizes three active agents: riluzole, edaravone (both intravenous and oral suspension formulations), and tofersen. In Japan, the 2023 ALS guidelines introduced three additional agents — oral edaravone, high-dose intramuscular mecobalamin, and tofersen — bringing the number of available anti-ALS agents to three or four in combination. Oral edaravone demonstrates pharmacokinetics comparable to the intravenous formulation with improved ease of administration, while high-dose mecobalamin has shown functional benefit when initiated early in the disease course. Tofersen, an antisense oligonucleotide designed to reduce SOD1 protein synthesis, represents the first gene-targeted therapy approved for SOD1-variant ALS. However, the long-term safety, efficacy, and potential synergistic or additive effects of these agents in combination remain to be clarified through real-world data and prospective registries.

Beyond approved agents, adjunctive and exploratory strategies are also under investigation. Natural compounds — including alpha-lipoic acid, biotin, and bioactive molecules such as curcumin, resveratrol, luteolin, quercetin, and catechins — exhibit mechanistic convergence across pathways relevant to neurodegeneration, including NF-κB, MAPK, PI3K/AKT, Nrf2, apoptosis, and autophagy. While their antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective activities support biological plausibility as adjunctive strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection. Looking further ahead, the convergence of transcriptomics, artificial intelligence-based approaches, and precision neuro-nanomedicine is expected to redefine ALS from a single clinical entity into a spectrum of molecularly defined disorders, each potentially amenable to targeted or combination therapeutic intervention.

PrimeC's Place in the Evolving ALS Treatment Landscape

The ALS treatment landscape has undergone meaningful transformation over the past five years, driven by a broadening of both approved therapies and investigational modalities. Riluzole remains the foundational pharmacological intervention, modestly prolonging survival, while edaravone — approved by the FDA based on the pivotal phase 3 Study MCI186-19 — has been further validated through post hoc analyses demonstrating long-term clinical benefit across a broader spectrum of ALS disease trajectories than those defined in the original study criteria. Most significantly, the FDA approved the first antisense oligonucleotide (ASO) therapy for ALS, marking a paradigm shift toward genetically targeted intervention. Degrading ASOs have shown the greatest success in rarer forms of familial ALS, with early efforts now underway to address mis-splicing events in sporadic ALS and to clinically evaluate interference with genetic modifiers. Real-world data from global registries have complemented randomized controlled trial findings by characterising treatment performance across more heterogeneous patient populations, strengthening the evidence base for riluzole and edaravone in routine clinical practice.

Emerging cellular and immunomodulatory approaches have also generated substantive clinical data. A phase I trial of autologous stromal vascular fraction (SVF) therapy in 26 patients demonstrated an acceptable safety profile — with only five mild adverse events and no serious adverse events reported — alongside significant reductions in cerebrospinal fluid neurofilament light chain (NfL; Δ530.29 pg/mL, P = 0.039) and glial fibrillary acidic protein (GFAP; Δ622.23 pg/mL, P = 0.038), indicative of attenuation of neuroaxonal degeneration and astroglial activation. Although ALSFRS-R improvement was non-significant, 57.7% of participants self-reported symptomatic benefit, with female sex and shorter disease duration identified as predictors of response. Separately, autologous expanded regulatory T-lymphocytes (Tregs) combined with subcutaneous IL-2 were evaluated in a phase 1 study and a 24-week randomized controlled trial; Treg infusions were well tolerated, increased suppressive function, and in an open-label extension with dose escalation, six of eight participants demonstrated slow to no progression. GLP-1 receptor agonists have also entered the neurological investigation space, with preclinical ALS models showing consistent benefit, though clinical outcomes remain variable; newer agents such as NLY01 and tirzepatide are under development specifically to enhance CNS penetration and efficacy.

A comprehensive review of literature spanning January 2016 to June 2022 concluded that there is now convincing evidence of earlier diagnosis, improved disease monitoring, and more effective treatment of ALS — a sentiment echoed by the clinical advances observed since. Tofersen for SOD1-ALS has emerged as a particularly compelling proof-of-concept: four patients treated with monthly intrathecal tofersen for 15–26 months showed no significant clinical deterioration, with three demonstrating signs of motor function recovery and all four exhibiting CSF Nf-L levels declining to the normal range — a phenotype of chronic nonprogressive ALS not previously documented. While ALS remains incurable, the convergence of genetic, immunological, and combination pharmacological strategies — including the PARADIGM trial data for PrimeC — signals that a cautiously optimistic view of ALS management is now well-supported by the published evidence.

PrimeC's ALS Advance: Repurposing for a New Therapeutic Era

The recent announcement regarding NeuroSense Therapeutics' PrimeC marks a significant moment in the pursuit of effective treatments for amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with profoundly limited therapeutic options. The Phase IIb PARADIGM study demonstrated a statistically significant reduction in TDP-43 protein levels, a crucial biomarker for ALS progression, alongside promising clinical benefits including slowed disease decline and a median survival advantage. This robust data has paved the way for FDA clearance of the global Phase III PARAGON study, signaling a potential new era for ALS management.

PrimeC's innovative approach combines ciprofloxacin and celecoxib, targeting multiple pathological pathways implicated in ALS, including brain inflammation, abnormal microRNA activity, and iron buildup. Existing literature supports ciprofloxacin's ability to modulate microglial inflammation, providing a scientific rationale for its inclusion in this combination. If the Phase III trial replicates these positive outcomes, PrimeC could emerge as a groundbreaking, disease-modifying therapy, fundamentally reshaping the standard of care for ALS patients. This success would also validate the strategic value of drug repurposing, offering a potentially faster and more cost-effective development pathway for other complex neurological conditions.

However, the path forward is not without considerations. Ciprofloxacin, while demonstrating anti-inflammatory properties in specific contexts, is a broad-spectrum antibiotic with a known safety profile that includes neuropsychiatric adverse events such as acute psychosis and antibiotic-associated encephalopathy. Its ability to inhibit GABA-A receptors also raises concerns about potential convulsions, particularly in a patient population already susceptible to neurological vulnerabilities. Furthermore, ciprofloxacin is implicated in numerous drug-drug interactions, notably with tizanidine, and shows a high incidence of potential interactions in older adults, necessitating meticulous co-medication management. The long-term use of an antibiotic also introduces the broader public health concern of antimicrobial resistance and potential alterations to the gut microbiome, which would require careful monitoring and stewardship. As NeuroSense advances into Phase III, balancing these known risks with the profound unmet need in ALS will be paramount, with the potential to deliver a truly transformative therapy.